Nuwellis, Inc.
NUWEHealthcareNASDAQMedical Devices · Last scanned Oct 24, 2026
Scan Results
Daily timeframeNuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. Valued at $1.2M, NUWE is a micro-cap name in its sector. The company provides Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure, as well as Aquadex SmartFlow system for temporary use in adult and pediatric patients.
Market Cap
$1.2M
Beta
0.09
P/E (TTM)
0.00
P/E (Fwd)
-0.12
EPS (TTM)
$435.92
EPS (Fwd)
$-2.59
ROE
—
ROA
-87.8%
Cash
$3.9M
Total Debt
$200,000
Free CF
-$11.4M
52W Change
-99.7%
Annual Financials
Cash vs Debt
Where NUWE stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, NUWE finished 96.21% below its 150-day moving average ($14.79) and 98.11% below its 200-day moving average ($29.58). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NUWE overbought or oversold?
At the October 20, 2026 close, NUWE's RSI(14) was 22.9, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Nuwellis, Inc. holds $3.9M in cash against $200K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$11.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Revenue has been relatively flat, moving from $8.5M (2022) to $8.3M (2025).
The relatively low beta of 0.09 suggests NUWE is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Nuwellis, Inc.'s trajectory.